ABSTRACT
The oncogene HER2 is an important molecular target in oncology because it is associated with aggressive disease and the worst prognosis. The development of non-invasive imaging techniques and target therapies using monoclonal antibodies is a rapidly developing field. Thus, this work proposes the study of the radioimmunotheranostic pair, [111In]In-DTPA-trastuzumab and [177Lu]Lu-DOTA-trastuzumab, evaluating the influence of the chelating agents and radionuclides on the biological properties of the radioimmunoconjugates (RICs). The trastuzumab was immunoconjugated with the chelators DTPA and DOTA and radiolabeled with [111In]InCl3 and [177Lu]LuCl3, respectively. The stability of the RICs was evaluated in serum, and the immunoreactive and internalization fractions were determined in SK-BR-3 breast cancer cells. The in vivo pharmacokinetics and dosimetry quantification and the ex vivo biodistribution were performed in normal and SK-BR-3 tumor-bearing mice. The data showed that there was no influence of the chelating agents and radionuclides on the immunoreactive and internalization fractions of RICs. In contrast, they influenced the stability of RICs in serum, as well as the pharmacokinetics, dosimetry and biodistribution profiles. Therefore, the results showed that the nature of the chelating agent and radionuclide could influence the biological properties of the radioimmunotheranostic pair.
ABSTRACT
A study directed to the cytogenetic and dosimetric aspects of radionuclides of medical interest is very valuable, both for an accurate evaluation of the dose received by the patients, and consequently of the genetic damage, and for the optimization of therapeutic strategies. Cytogenetic and dosimetric effects of (131)I in lymphocytes of thyroidectomized differentiated thyroid cancer (DTC) patients were evaluated through chromosome aberration (CA) technique: Euthyroid patients submitted to recombinant human thyroid-stimulating hormone (rhTSH) therapy (group A) were compared with hypothyroid patients left without levothyroxine treatment (group B). CA analysis was carried out prior to and 24 h, 1 week, 1 month and 1 year after radioiodine administration (4995-7030 MBq) in both groups. An activity-response curve of (131)I (0.074-0.740 MBq/mL) was elaborated, comparing dicentric chromosomes in vivo and in vitro in order to estimate the absorbed dose through Monte Carlo simulations. In general, radioiodine therapy induced a higher total CA rate in hypothyroid patients as compared to euthyroid patients. The frequencies of dicentrics obtained in DTC patients 24 h after treatment were equivalent to those induced in vitro (0.2903 ± 0.1005 MBq/mL in group A and 0.2391 ± 0.1019 MBq/mL in group B), corresponding to absorbed doses of 0.65 ± 0.23 Gy and 0.53 ± 0.23 Gy, respectively. The effect on lymphocytes of internal radiation induced by (131)I therapy is minimal when based on the frequencies of CA 1 year after the treatment, maintaining a higher quality of life for DTC patients receiving rhTSH-aided therapy.
Subject(s)
Chromosome Aberrations , Iodine Radioisotopes , Thyroid Neoplasms/drug therapy , Adult , Dose-Response Relationship, Radiation , Humans , Iodine Radioisotopes/administration & dosage , Iodine Radioisotopes/therapeutic use , Iodine Radioisotopes/toxicity , Lymphocytes/metabolism , Lymphocytes/radiation effects , Middle Aged , Radiation Dosage , Thyrotropin Alfa/pharmacology , Thyroxine/therapeutic useABSTRACT
PURPOSE: To evaluate exposure and dosimetry to family members and environment due to outpatient radioiodine therapy of differentiated thyroid carcinoma. METHODS: Twenty patients were treated with 100-150mCi of iodine-131 on an out-patient basis. Family members dosimetry (n = 27) and potential doses inside the house were measured with thermoluminescent dosimeters. Surface contamination and radioactive wastes were also monitored. RESULTS: Less than 1.0 mSv doses were found in 26 co-habitants and 2.8 mSv in a single case (inferior to the acceptable value of 5.0 mSv/procedure). Potential doses in the houses were inferior to 0.25 mSv, excluding the patients bedroom (mean value = 0.69 mSv). Surface contamination (mean = 4.2 Bq.cm-2) were below clearance levels. Radioactive wastes generated had a volume of 2.5 liters and a total activity estimated in 90 microCi, with a calculated exposure close to the background radiation levels. CONCLUSIONS: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals.
Subject(s)
Environmental Exposure/prevention & control , Family , Iodine Radioisotopes/administration & dosage , Radiation Protection/methods , Thyroid Neoplasms/radiotherapy , Adult , Ambulatory Care , Female , Humans , Iodine Radioisotopes/adverse effects , Male , Middle Aged , Radiation Protection/standards , Radiotherapy Dosage , Thermoluminescent Dosimetry , Thyroid Neoplasms/surgery , ThyroidectomyABSTRACT
OBJETIVO: Determinar exposições decorrentes da radioiodoterapia ambulatorial do carcinoma diferenciado da tireoide (CDT) sobre os familiares dos pacientes e o meio ambiente. MÉTODOS: Administraram-se 100 a 150 mCi de (131I)NaI para tratamento ambulatorial de 20 pacientes com CDT. Monitorizaram-se com dosímetros termoluminescentes as doses de radiação recebidas por familiares (n = 27) e potenciais de dose nas residências. Também foram monitorizadas contaminação de superfície e rejeitos radioativos. RESULTADOS: Registraram-se doses < 1,0 mSv em 26 acompanhantes e 2,8 mSv em um caso, inferiores ao aceitável para exposições médicas (5,0 mSv/procedimento). Excetuando-se o quarto dos pacientes (média = 0,69 mSv), determinou-se potencial de dose nas residências < 0,25 mSv. A contaminação de superfícies (4,2 Bq.cm-2) não ultrapassou níveis de liberação, sem representar riscos mesmo em simulações do pior cenário. Os rejeitos radioativos tiveram volume de 2,5 litros e atividade estimada em 90 µCi (média = 4,5 µCi/paciente). CONCLUSÕES: Não foi constatado impacto radiológico ao meio ambiente ou aos familiares de pacientes tratados ambulatorialmente com 100 a 150 mCi de iodo-131 e acompanhados por profissionais qualificados.
PURPOSE:To evaluate exposure and dosimetry to family members and environment due to outpatient radioiodine therapy of differentiated thyroid carcinoma. METHODS: Twenty patients were treated with 100-150mCi of iodine-131 on an out-patient basis. Family members dosimetry (n = 27) and potential doses inside the house were measured with thermoluminescent dosimeters. Surface contamination and radioactive wastes were also monitored. RESULTS: Less than 1.0 mSv doses were found in 26 co-habitants and 2.8 mSv in a single case (inferior to the acceptable value of 5.0 mSv/procedure). Potential doses in the houses were inferior to 0.25 mSv, excluding the patients bedroom (mean value = 0.69 mSv). Surface contamination (mean = 4.2 Bq.cm-2) were below clearance levels. Radioactive wastes generated had a volume of 2.5 liters and a total activity estimated in 90 µCi, with a calculated exposure close to the background radiation levels. CONCLUSIONS: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Environmental Exposure/prevention & control , Family , Iodine Radioisotopes/administration & dosage , Radiation Protection/methods , Thyroid Neoplasms/radiotherapy , Ambulatory Care , Iodine Radioisotopes/adverse effects , Radiotherapy Dosage , Radiation Protection/standards , Thermoluminescent Dosimetry , Thyroidectomy , Thyroid Neoplasms/surgeryABSTRACT
OBJETIVO: O objetivo deste trabalho consiste em estudar a influência da resolução espacial da sonda gama Europrobe que é utilizada em cirurgia radioguiada. MATERIAIS E MÉTODOS: Na técnica de cirurgia radioguiada, após a injeção de um radiotraçador no tumor primário, é utilizada uma sonda detectora de radiação gama a fim de determinar a localização do linfonodo sentinela. Para simular a região dos pontos de injeção do radiotraçador e o linfonodo sentinela, duas fontes de Tc-99m, com 20,42 MBq e 0,70 MBq, foram posicionadas no interior de um recipiente preenchido com água. Em seguida, com a janela de entrada da sonda coberta com um colimador, realizou-se varredura sobre a superfície da água. Assim, foi possível registrar a taxa de contagens variando-se a distância lateral da sonda em relação às duas fontes, as quais foram separadas por uma distância variando entre 30 mm e 60 mm. RESULTADOS: Os resultados mostraram que o uso do colimador contribui para melhorar a resolução espacial da sonda, permitindo a identificação do linfonodo sentinela distante até 30 mm do ponto de injeção. CONCLUSÃO: Esse estudo permite concluir que a sonda Europrobe, quando utilizada com capa colimadora com orifício central de 3,5 mm de diâmetro, é capaz de identificar o linfonodo sentinela posicionado a até 30 mm de distância em relação à região do ponto de injeção do radiotraçador.
OBJECTIVE: The aim of the present study is to evaluate the performance of the Europrobe gamma probe spatial resolution in radioguided surgery. MATERIALS AND METHODS: In the radioguided surgery technique, after a radiotracer injection into the primary tumor, a gamma detector probe is utilized to determine the localization of the sentinel lymph node. In order to simulate the region of the radiotracer injection the sentinel lymph node, two Tc-99m sources, with 20.42 MBq and 0.70 MBq, were positioned in a water-filled tank. With a collimator cap attached to the probe, scans over the water surface were made. So, the count rate was measured by means of lateral displacement of the probe in relation to the both sources with distances ranging between 30 mm and 60 mm. RESULTS: Results showed that the use of the collimator contributes to improve the spatial resolution of the probe allowing the identification of a sentinel lymph node within a distance up to 30 mm from the radiotracer injection point. CONCLUSION: The utilization of a collimator cap with a 3.5 mm diameter central orifice on a Europrobe gamma probe, allows the identification of a sentinel lymph node within a distance up to 30 mm from the radiotracer injection point.
Subject(s)
Surgery, Computer-Assisted/methods , Lymph Nodes , Monitoring, Intraoperative , Surgery, Computer-Assisted , Diagnostic Imaging/instrumentation , Gamma CamerasABSTRACT
The mathematical phantom of the Brazilian man was developed because many anatomical differences exist between South Americans, Europeans and North Americans. The objective of this work was to compare specific absorbed fractions (SAF) obtained for a model of the Brazilian adult male with those for the reference adult calculated by Snyder et al. in 1974 and to evaluate the importance of these new values in calculating radiation doses in diagnosis and therapy. The length and mass of the total body for the Brazilian man phantom were obtained from tables provided by the Brazilian government (IBGE) in which the masses of organs were measured atautopsy. Monte Carlo methods (using the ALGAM-97 computer code) were applied to calculate SAF for internal organs and the total body. The mathematical phantom designed by Snyder et al. represents very closely Reference Man, as defined in ICRP publication 23. SAF for the whole body were not more than 15% different between the two phantoms. The differences between both models are more significant for individual organs. When the source organ is the lung and red marrow is the target, for initial photon energy of 10 keV, the results obtained indicate that marrow receives 64% more dose in Brazilian model than in the Reference Man model. Eighty tables were made for 97 distinct organs (target-source) and the comparison made between the, Brazilian man and Reference man.
